VIDEO: Xipere demonstrates durability, safety in real-world setting

In this Healio Video Perspective from the Retina Society meeting, Steven Yeh, MD, of Stanley M. Truhlsen Eye Institute, discusses Xipere for the treatment of noninfectious uveitis-associated macular edema.

A study investigated nearly 800 eyes of 750 patients treated with Xipere (triamcinolone acetonide injectable suspension, Bausch + Lomb). Notably, more than 40% of patients in the study were diagnosed with glaucoma.

“Patients who received Xipere, a single dose, did not require rescue therapy, with the majority of patients, around 88%, receiving only a single dose of Xipere and only 14% showing an elevation in intraocular pressure,” he said.

Reference:

• Singer M. Durability of suprachoroidal injection of triamcinolone acetonide injectable suspension for uveitic macular edema and use of rescue therapy in clinical practice. Presented at: Retina Society meeting; Sept. 11-15, 2024; Lisbon, Portugal.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures:
Yeh reports consulting for Bausch + Lomb and being an investigator in the PEACHTREE trial.

Read more about

This post was originally published on this site